2015
Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis
Risch HA, Yu H, Lu L, Kidd MS. Detectable Symptomatology Preceding the Diagnosis of Pancreatic Cancer and Absolute Risk of Pancreatic Cancer Diagnosis. American Journal Of Epidemiology 2015, 182: 26-34. PMID: 26049860, PMCID: PMC4479115, DOI: 10.1093/aje/kwv026.Peer-Reviewed Original ResearchConceptsPancreatic cancer diagnosisAbsolute riskPancreatic cancerRecent diagnosisRisk factorsEnd Results (SEER) incidence dataUS Surveillance EpidemiologyCancer diagnosisCurrent cigarette smokingLow lifetime riskABO blood groupDiabetes mellitusSurveillance EpidemiologyCigarette smokingSurvival durationLifetime riskHigh riskPancreatic causesCancerBlood groupRisk estimatesDiagnosisIncidence dataSymptomatologyRisk
2013
PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer
Akbari MR, Lepage P, Rosen B, McLaughlin J, Risch H, Minden M, Narod SA. PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer. Journal Of The National Cancer Institute 2013, 106: djt323. PMID: 24262437, DOI: 10.1093/jnci/djt323.Peer-Reviewed Original ResearchMeSH KeywordsAgedBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCanadaCase-Control StudiesFemaleGenetic Predisposition to DiseaseHeterozygoteHumansIncidenceLeukocytesMiddle AgedMutationOdds RatioOvarian NeoplasmsPhosphoprotein PhosphatasesProportional Hazards ModelsProtein Phosphatase 2CRisk AssessmentRisk FactorsConceptsCase patientsWhite blood cellsOvarian cancerControl subjectsOvarian cancer case patientsFemale first-degree relativesBlood cellsCancer case patientsFirst-degree relativesLifetime riskBreast cancerFamily historyMutation carriersPatientsCancerPast historyTruncating mutationsBreastRiskMutationsSubjectsCellsNoncarriersMortalityWomen
1998
Oral Contraceptives and the Risk of Hereditary Ovarian Cancer
Narod S, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet J, Ponder B, Klijn J. Oral Contraceptives and the Risk of Hereditary Ovarian Cancer. New England Journal Of Medicine 1998, 339: 424-428. PMID: 9700175, DOI: 10.1056/nejm199808133390702.Peer-Reviewed Original ResearchConceptsOral contraceptive useHereditary ovarian cancerOvarian cancerOral contraceptivesControl womenBRCA2 genesPathogenic mutationsCase-control studyHigh lifetime riskDuration of useYear of birthLifetime riskOdds ratioBRCA2 mutationsLifetime historyHereditary formsCancerBRCA1 mutationsContraceptivesWomenPatientsRiskMore yearsPast useBRCA1
1989
Mortality from Breast Cancer after Irradiation during Fluoroscopic Examinations in Patients Being Treated for Tuberculosis
Miller A, Howe G, Sherman G, Lindsay J, Yaffe M, Dinner P, Risch H, Preston D. Mortality from Breast Cancer after Irradiation during Fluoroscopic Examinations in Patients Being Treated for Tuberculosis. New England Journal Of Medicine 1989, 321: 1285-1289. PMID: 2797101, DOI: 10.1056/nejm198911093211902.Peer-Reviewed Original ResearchConceptsBreast cancerRelative riskFluoroscopic examinationRadiation-induced breast cancerFirst exposureLinear dose-response relationUse of mammographyYears of ageDose-response relationNumber of deathsTherapeutic pneumothoraxAsymptomatic womenExcess riskLifetime riskAdditive riskCancerWomenSubstantial proportionSmall benefitAgeRadiation dosesRiskTuberculosisMortalityExposure